Solifenacin - Astellas Pharma

Drug Profile

Solifenacin - Astellas Pharma

Alternative Names: Bispec; Solifenacin succinate; Vesicare; Vesicare OD; VESIcare®; YM 67905; YM 905

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Antispasmodics; Esters; Isoquinolines; Quinuclidines; Small molecules; Urologics
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • No development reported Irritable bowel syndrome

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Mar 2018 Registered for Overactive bladder (In adolescents, In children) in Netherlands (PO)
  • 30 Apr 2017 Preregistration for Overactive bladder (In children, In infants) in European Union (PO) (Astellas Pharma pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top